Administrative Core The Administrative Core contains two components: administration and senior leadership. The research, clinical care, education, and outreach components of the University of Pittsburgh Cancer Institute?s (UPCI?s) mission are enabled by an efficient administrative infrastructure led by UPCI?s Associate Director for Research Administration, Maryann Donovan PhD, MPH, and the vision and guidance provided by UPCI?s experienced Senior Leadership, under UPCI Director, Nancy E. Davidson, MD.
The specific aims of administration are to: Refine administrative processes so that they are more effective and efficient, and less burdensome to UPCI Faculty and Leadership, 2) Adopt new technologies and tools for accomplishing administrative functions, and 3) Improve communication and streamline operations to improve services for researchers, including services provided by UPCI Shared Resources. In collaboration with UPCI, University of Pittsburgh, and UPMC departments, UPCI administration performs or assists in performing essential UPCI functions that include: budget preparation and expenditure monitoring; grant, contract and philanthropic funds management; space allocation and renovation; shared equipment purchase and operational management; shared resource operational management; faculty recruitments; meeting coordination; pilot project program development and implementation; planning and evaluation activities; UPCI membership maintenance and productivity tracking; and event and funding opportunity communications. UPCI?s Senior Leadership Group includes the Cancer Center Director (Dr. Davidson), UPCI Deputy Director (Edward Chu, MD), and the Associate Directors for Basic Research (Shivendra Singh, PhD), Translational Research (Robert L. Ferris, MD, PhD), Cancer Control and Population Sciences (Jian-Min Yuan, MD, PhD), Clinical Investigation (Adam Brufsky, MD, PhD), and Research Administration (Dr. Donovan). Individually accomplished, with strong scientific and leadership achievements, they have worked together as a Senior Leadership Group since 2012.
The specific aims for Senior Leadership are to: 1) Implement, continuously review, and refresh the 2014 Strategic Vision for UPCI, 2) Monitor progress at achieving the goals planned for the years 2014-2018, 3) Increase focus on translational advancement of discoveries made at UPCI, 4) Increase focus on research addressing UPCI?s catchment area, 5) Enable processes to support interaction with other Cancer Centers, and 6) Assist the Cancer Center Director in developing a vision for the years beyond 2018. During the current funding cycle Senior Leadership has developed and implemented an interactive vision-setting process for strategic planning; revised the process for oversight of Shared Resources; led, participated in, and promoted collaborative team science efforts directed at basic discovery and scientific advancement; and established new oversight committees to review and plan research that is focused on UPCI?s catchment area, and educational and training opportunities that strengthen UPCI?s Research Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-30
Application #
9543982
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications